Victor Wembanyama rookie card prices jumped after the Spurs reached the NBA Finals, including Silver Prizm PSA 10 sales above $3,300.
There is no shortage of ways to navigate the hobby, even with the news from PSA about value grading being suspended.
Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with Pluvicto plus standard of care (ARPI + ADT) in PSMAdditionConsistent ...
The most popular grading company in the hobby has seen a monumental increase in submissions, including record breaking numbers in May. And while they have changed turnaround times and required ...
The UK's National Screening Committee has recommended that only a very small group of men at high risk of prostate cancer ...
PSA reported that inflation in April settled at 1.4 percent, slower than the 1.8 percent recorded in March and significantly lower than the 3.8 percent in April 2024. It was also the lowest inflation ...
An updated Cochrane review has concluded there is evidence that PSA screening reduces prostate cancer deaths. The analysis of 800,000 men aged 50 to 74 years who took part in large trials across ...
Enzalutamide Plus Leuprolide Extends Treatment Suspension in Biochemically Recurrent Prostate Cancer
An ITT reanalysis assigning 0-month suspension to non-suspenders addressed imbalance in suspension rates (90% combination, 86 ...
MedPage Today on MSN
Evidence Mounts for Darolutamide Plus ADT in Hormone-Sensitive Prostate Cancer
U.S. study supports findings from a global trial using an external control arm ...
The ARASEC study prospectively examined darolutamide plus ADT in US men with mHSPC, but used a historical control group receiving ADT monotherapy from the phase 3 CHAARTED trial for matching and ...
The Bangko Sentral ng Pilipinas expects May 2026 inflation to remain high at 7.1 percent to 7.9 percent, driven by rising costs of rice, vegetables, and meat, alongside a weaker peso.
Data collected between May 4 and May 9, 2026 through Spherix Global Insights’ Launch Dynamix™ service suggest Bristol Myers Squibb’s Sotyktu (deucravacitinib) is beginning to gain traction in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results